Helical beta-peptide inhibitors of the p53-hDM2 interaction

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Structural Biology

Background:

• The interaction between p53 and hDM2 is a critical target for cancer therapy.
• A specific alpha-helix within the p53 trans-activation domain (p53AD) is recognized by hDM2.
• A functional epitope on the p53AD helix (residues F19, W23, L26) is crucial for binding affinity.

Purpose of the Study:

• To design and synthesize novel beta3-peptides that recapitulate the functional epitope of the p53AD helix.
• To investigate if these beta3-peptides can bind to hDM2 with high affinity.
• To establish a generalizable strategy for peptide-based disruption of protein-protein interactions.

Main Methods:

• Hypothesized that presenting key p53AD residues (F19, W23, L26) on a stabilized beta3-peptide 14-helix would mimic the natural interaction.
• Synthesized a series of beta3-peptides designed to adopt a 14-helix secondary structure in aqueous solution.
• Characterized the structural properties and binding affinity of the designed beta3-peptides to hDM2.

Main Results:

• Developed beta3-peptides that exhibit significant 14-helix structure in water.
• Identified a beta3-peptide that binds to a surface cleft on hDM2 with nanomolar affinity.
• Demonstrated that secondary structure homology can be a basis for designing functional peptide mimics.

Conclusions:

• Beta3-peptides can effectively mimic the secondary structure and functional epitope of alpha-helices involved in critical protein-protein interactions.
• This secondary structure-based design strategy offers potential advantages over traditional alpha-peptide modifications for therapeutic applications.
• The developed beta3-peptides represent promising leads for disrupting the p53.hDM2 interaction in cancer therapy.